journal
https://read.qxmd.com/read/38525693/indolent-t-cell-lymphoproliferation-of-the-gastrointestinal-tract-an-evolving-disease-entity
#1
Luke Wang, Elaine Koh, Beena Kumar, Michael S Y Low
Background: Indolent T cell lymphoproliferation of the gastrointestinal tract is a novel entity recently added to the 2016 WHO classification of lymphoid neoplasms. Classically, these patients demonstrate an immunophenotype consistent with T cell proliferation and can be either CD4-positive or CD8-positive but with a low Ki67 index, highlighting the indolent nature of this disease compared to its more aggressive T cell lymphoma counterparts such as enteropathy-associated T cell lymphoma and monomorphic epitheliotropic intestinal T cell lymphoma...
March 22, 2024: Hematology Reports
https://read.qxmd.com/read/38534887/navigating-lymphomas-through-bcr-signaling-and-double-hit-insights-overview
#2
REVIEW
Antonella Argentiero, Alessandro Andriano, Donatello Marziliano, Vanessa Desantis
Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating from B, T, or NK lymphocytes. They represent approximately 4-5% of new cancer cases and are classified according to the revised WHO system based on cell lineage, morphology, immunophenotype, and genetics. Diagnosis requires adequate biopsy material, though integrated approaches are used for leukemic presentations. Molecular profiling is improving classification and identifying prognostic markers. Indolent NHLs, such as follicular lymphoma and marginal zone lymphoma, typically pursue a non-aggressive clinical course with long survival...
March 21, 2024: Hematology Reports
https://read.qxmd.com/read/38534886/drug-drug-interactions-of-fxi-inhibitors-clinical-relevance
#3
REVIEW
Nicola Ferri, Elisa Colombo, Alberto Corsini
Inhibitors of the factor FXI represent a new class of anticoagulant agents that are facing clinical approval for the treatment of acute coronary syndrome (ACS), venous thromboembolism (VTE), and stroke prevention of atrial fibrillation (AF). These new inhibitors include chemical small molecules (asundexian and milvexian), monoclonal antibodies (abelacimab, osocimab, and xisomab), and antisense oligonucleotides (IONIS-FXIRX and fesomersen), and thus, they have very peculiar and different pharmacokinetic and pharmacodynamic properties...
March 21, 2024: Hematology Reports
https://read.qxmd.com/read/38534885/the-cardiovascular-event-risk-associated-with-tyrosine-kinase-inhibitors-and-the-lipid-profile-in-patients-with-chronic-myeloid-leukemia
#4
JOURNAL ARTICLE
María Nieves Saez Perdomo, Ruth Stuckey, Elena González-Pérez, Santiago Sánchez-Sosa, Paula Estupiñan-Cabrera, Sunil Lakhwani Lakhwani, José David González San Miguel, Nuria Hernanz Soler, Marina Gordillo, Gloria González Brito, María Tapia-Torres, Ana Ruano, Adrián Segura-Díaz, Hugo Luzardo, Cristina Bilbao-Sieyro, María Teresa Gómez-Casares
BACKGROUND: Second- and third-generation tyrosine kinase inhibitors (TKIs) are now available to treat chronic-phase chronic myeloid leukemia (CP-CML) in the first and second line. However, vascular adverse events (VAEs) have been reported for patients with CML treated with some TKIs. METHODS: We retrospectively evaluated the cumulative incidence (CI) and cardiovascular risk for 210 patients included in the Canarian Registry of CML. RESULT: With a mean follow up of 6 years, 19/210 (9...
March 12, 2024: Hematology Reports
https://read.qxmd.com/read/38534884/factor-vii-deficiency-in-systemic-mastocytosis-with-an-associated-myeloid-neoplasm
#5
Giorgio Rosati, Sofia Camerlo, Alessandro Fornari, Valerio Marci, Barbara Montaruli, Alessandro Morotti
Factor VII (FVII) deficiency is a rare bleeding disorder that can be classified as congenital or acquired, and the majority of acquired cases are due to vitamin K deficiency or liver disease. Isolated acquired FVII deficiency is a rare occurrence and has been associated with inhibitors or auto-antibodies. Here, we describe a patient with polycythemia vera who developed systemic mastocytosis and FVII deficiency simultaneously. FVII deficiency was not caused by inhibitors and improved with antineoplastic treatment...
March 12, 2024: Hematology Reports
https://read.qxmd.com/read/38534883/uncommon-presentation-of-sarcoidosis-with-severe-thrombocytopenia-and-hemorrhagic-diathesis
#6
Dorela Lame, Michelangelo Pianelli, Shahram Kordasti, Erika Morsia, Attilio Olivieri, Antonella Poloni
Sarcoidosis, a multi-organ system disease, often presents insidiously. Thrombocytopenia in sarcoidosis is frequent because of hypersplenism, granulomas infiltrating the bone marrow, or immune thrombocytopenia (ITP). The diagnosis of ITP relies on exclusionary criteria, given the absence of a definitive laboratory diagnostic feature. In the era prior to modern ITP management, sarcoidosis-associated ITP was known to manifest severely, often showing resistance to treatment and an increased risk of mortality. In this case, we present a young male who was admitted to a district hospital's emergency room, displaying symptoms of hematuria, gingival bleeding, and a petechial rash...
March 4, 2024: Hematology Reports
https://read.qxmd.com/read/38534882/impact-of-skeletal-muscle-depletion-on-patients-with-myelodysplastic-syndrome-treated-with-azacitidine
#7
JOURNAL ARTICLE
Eri Takada, Nobuhiko Nakamura, Yuto Kaneda, Kenji Fukuno, Shin Lee, Kei Fujita, Tetsuji Morishita, Yoshikazu Ikoma, Takuro Matsumoto, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Hisashi Tsurumi, Masahito Shimizu
BACKGROUND: Azacitidine (AZA) is the standard treatment for patients with high-risk myelodysplastic syndromes (MDS). The impact of skeletal muscle depletion (SMD), which is associated with outcomes of hematological malignancies, on the clinical course of MDS patients treated with AZA was investigated. METHODS: This retrospective, observational study included 50 MDS patients treated with AZA. Muscle mass was evaluated using the skeletal muscle index (SMI), which is the area of muscle mass at the third lumbar vertebra on CT images divided by the square of the height...
February 28, 2024: Hematology Reports
https://read.qxmd.com/read/38534881/primary-bone-lymphoma-of-the-scapula
#8
Josip Lovaković, Inga Mandac Smoljanović, Andro Matković, Tomislav Smoljanović
Primary bone lymphoma of the scapula is a rare tumor that usually causes local pain. The presented patient suffered for two years from paresthesia, tingling, numbness, and edema of the little and ring fingers. The 45-year-old man underwent several radiological and neurological assessments of the palm, elbow, and neck before radiographs revealed a tumor of the left shoulder. Once diffuse large B-cell lymphoma was confirmed, immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and methylprednisolone (R-CHOP) started...
February 28, 2024: Hematology Reports
https://read.qxmd.com/read/38534880/successful-bone-marrow-transplantation-in-a-patient-with-acute-myeloid-leukemia-developed-from-severe-congenital-neutropenia-using-modified-chemotherapy-and-conditioning-regimen-for-leukemia
#9
Risa Matsumura, Shinji Mochizuki, Yusuke Morishita, Hiroko Hayakawa, Shuhei Karakawa, Hiroshi Kawaguchi, Satoshi Okada, Nobuyuki Hyakuna, Masao Kobayashi
Severe congenital neutropenia (SCN) is characterized by chronic neutropenia with recurrent infections from early infancy and a predisposition to myelodysplastic syndrome/acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with SCN who develop myelodysplastic syndrome/AML. We report an 8-year-old girl with SCN carrying an ELANE mutation that had been refractory to granulocyte colony-stimulating factor. The patient experienced recurrent infections and then developed AML...
February 26, 2024: Hematology Reports
https://read.qxmd.com/read/38534879/prevalence-outcomes-and-impact-of-disease-related-complications-in-the-survival-of-multiple-myeloma-patients
#10
JOURNAL ARTICLE
Wachiralak Tothong, Adisak Tantiworawit, Lalita Norasetthada, Chatree Chai-Adisaksopha, Teerachat Punnachet, Nonthakorn Hantrakun, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Ekarat Rattarittamrong
There are limited data regarding the impact of disease-related complications on the survival of multiple myeloma (MM) patients. The primary objective of this study was to determine the prevalence of disease-related complications, including hypercalcemia, renal insufficiency, anemia, and bone lytic lesions in MM patients. The secondary objectives were to determine clinical characteristics, treatment outcomes, and the association of disease-related complications and mortality. A retrospective chart review of MM patients from November 2014 to December 2019 was conducted...
February 21, 2024: Hematology Reports
https://read.qxmd.com/read/38390940/predictive-model-for-occurrence-of-febrile-neutropenia-after-chemotherapy-in-patients-with-diffuse-large-b-cell-lymphoma-a-multicenter-retrospective-observational-study
#11
JOURNAL ARTICLE
Masaya Morimoto, Yuma Yokoya, Kikuaki Yoshida, Hideki Kosako, Yoshikazu Hori, Toshiki Mushino, Shinobu Tamura, Reiko Ito, Ryosuke Koyamada, Takuya Yamashita, Shinichiro Mori, Nobuyoshi Mori, Sachiko Ohde
Febrile neutropenia (FN) is a major concern in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL); however, the overall risk of FN is difficult to assess. This study aimed to develop a model for predicting the occurrence of FN in patients with DLBCL. In this multicenter, retrospective, observational analysis, a multivariate logistic regression model was used to analyze the association between FN incidence and pretreatment clinical factors. We included adult inpatients and outpatients (aged ≥ 18 years) diagnosed with DLBCL who were treated with chemotherapy...
February 7, 2024: Hematology Reports
https://read.qxmd.com/read/38390939/the-gut-microbiome-correlated-to-chemotherapy-efficacy-in-diffuse-large-b-cell-lymphoma-patients
#12
JOURNAL ARTICLE
Zhuo-Fan Xu, Li Yuan, Yan Zhang, Wei Zhang, Chong Wei, Wei Wang, Danqing Zhao, Daobin Zhou, Jingnan Li
The gut microbiome (GMB) has been extensively reported to be associated with the development and prognosis of human diseases. This study aims to investigate the relationship between GMB composition and chemotherapy efficacy in diffuse large B-cell lymphoma (DLBCL). We demonstrated that DLBCL patients at diagnosis have altered GMB compositions. Significant enrichment of the Proteobacteria phylum in DLBCL patients was observed. Gene analysis showed a high abundance of virulence factors genes. We found baseline GMB to be associated with clinical outcomes...
January 22, 2024: Hematology Reports
https://read.qxmd.com/read/38247996/survival-outcomes-of-patients-with-mantle-cell-lymphoma-a-retrospective-15-year-real-life-study
#13
JOURNAL ARTICLE
Emanuele Cencini, Natale Calomino, Marta Franceschini, Andreea Dragomir, Sara Fredducci, Beatrice Esposito Vangone, Giulia Lucco Navei, Alberto Fabbri, Monica Bocchia
Mantle cell lymphoma (MCL) prognosis has significantly improved in recent years; however, the possible survival benefit of new treatment options should be evaluated outside of clinical trials. We investigated 73 consecutive MCL patients managed from 2006 to 2020. For younger patients <65 years old, the median PFS was 72 months and we reported a 2-year, 5-year, and 10-year PFS of 73%, 62%, and 41%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 88%, 82%, and 66%. For patients aged 75 years or older, the median PFS was 36 months and we reported a 2-year, 5-year, and 10-year PFS of 52%, 37%, and 37%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 72%, 55%, and 55%...
January 18, 2024: Hematology Reports
https://read.qxmd.com/read/38247995/manifestation-of-pancytopenia-associated-with-covid-19-as-paroxysmal-nocturnal-hemoglobinuria-pnh-and-aplastic-anemia-aa
#14
Jeff Justin Aguilar, Vikram Dhillon, Suresh Balasubramanian
We report two cases of pancytopenia in patients after recovering from a mild COVID-19, now presenting as paroxysmal nocturnal hemoglobinuria (PNH) and aplastic anemia. These cases illustrate a common pathway whereby a viral trigger causes the clonal expansion of a hematological disorder. Although the association of both cases with COVID-19 is temporal and COVID-19 may be an incidental diagnosis, the growing evidence related to the hematological effects of SARS-CoV-2 infection highlights the need for further investigation into the hematological consequences of COVID-19, particularly in the post-pandemic era...
January 17, 2024: Hematology Reports
https://read.qxmd.com/read/38247994/emerging-role-of-18-f-flt-pet-ct-in-lymphoid-malignancies-a-review-of-clinical-results
#15
REVIEW
Anna Giulia Nappi, Giulia Santo, Lorenzo Jonghi-Lavarini, Alberto Miceli, Achille Lazzarato, Flavia La Torre, Francesco Dondi, Joana Gorica
Fluorine-18 fluorodeoxyglucose ([18 F]FDG) is nowadays the leading positron emission tomography (PET) tracer for routine clinical work-ups in hematological malignancies; however, it is limited by false positive findings. Notably, false positives can occur in inflammatory and infective cases or in necrotic tumors that are infiltrated by macrophages and other inflammatory cells. In this context, 3'-deoxy-3'-[18 F]fluorothymidine ([18 F]FLT) has been shown to be a promising imaging biomarker of hematological malignant cell proliferation...
January 11, 2024: Hematology Reports
https://read.qxmd.com/read/38247993/plasmacytoma-in-the-maxillary-jaw-a-diagnostic-and-therapeutic-challenge
#16
Sara Bernardi, Serena Bianchi, Ettore Lupi, Davide Gerardi, Guido Macchiarelli, Giuseppe Varvara
Plasmacytoma is a neoplastic disorder originating from plasma cells, with bone and soft tissue being common sites of manifestation. This report presents the clinical and radiological findings of a 65-year-old female patient who presented with an exophytic lesion in the upper right lateral incisor region. The lesion appeared as a unilocular radiotransparent area in imaging tests. Following an excisional biopsy, histological and immunohistochemical evaluations confirmed the presence of mature plasmacellular elements and small infiltrates of B and T lymphocytes...
January 4, 2024: Hematology Reports
https://read.qxmd.com/read/38247992/cutaneous-t-cell-lymphoma-ctcl-arising-post-kidney-transplant-a-review-of-clinical-variants-in-the-literature
#17
Jordan Pilkington, Sara Shalin, Henry K Wong
Post-transplant lymphoproliferative disease is a rare disorder with an annual incidence of 0.5% to 3.7%. Development of this disorder carries with it a poor prognosis. In this report, we describe a rare case of post-transplant primary cutaneous T-cell lymphoma (PT-CTCL) mycosis fungoides stage IIB in a patient following kidney transplantation, as well as a review of PT-CTCL reported in the literature. The treatment following diagnosis included bexarotene, cyclosporine, and prednisone. Currently, the patient is free from disease...
December 28, 2023: Hematology Reports
https://read.qxmd.com/read/38247991/feasibility-of-quality-of-life-assessment-in-patients-with-lymphoma-aged-%C3%A2-80-years-receiving-reduced-intensity-chemotherapy-a-single-institute-study
#18
JOURNAL ARTICLE
Satoshi Yamasaki
Quality of life (QOL) must be carefully monitored in older patients with lymphoma who are suitable for chemotherapy, but few reports have assessed QOL in older patients who received reduced-intensity chemotherapy. This study investigated QOL in patients with lymphoma aged ≥80 years to clarify the feasibility of such assessments following reduced-intensity chemotherapy. QOL was prospectively analyzed (using the QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-ACD)] and the SF-36® , a comprehensive survey of patient health) among 13 patients (seven women) aged ≥80 years with lymphoma who received reduced-intensity chemotherapy at 4-week intervals at Kyushu University Beppu Hospital between June 2022 and August 2023...
December 22, 2023: Hematology Reports
https://read.qxmd.com/read/38132279/humoral-and-cell-mediated-responses-to-sars-cov-2-vaccination-in-a-cohort-of-immunodeficient-patients
#19
JOURNAL ARTICLE
Federica Plano, Mojtaba Shekarkar Azgomi, Anna Maria Corsale, Corinne Spoto, Nadia Caccamo, Serena Meraviglia, Francesco Dieli, Paolo D'Angelo, Antonino Trizzino, Sergio Siragusa
This study delves into the intricate landscape of SARS-CoV-2 vaccine response in immunodeficient patients, focusing on the dynamics of both humoral and cell-mediated immunity. The cohort includes patients with common variable immunodeficiency (CVI), agammaglobulinemia (XLA), and combined immunodeficiency (CI). The findings reveal varying degrees of antibody production, with XLA patients exhibiting no measurable response but displaying a robust T-cell-mediated response. The study emphasizes the importance of considering both arms of the immune system in assessing vaccine immunogenicity, particularly in the context of immunodeficiency...
December 8, 2023: Hematology Reports
https://read.qxmd.com/read/38132278/blastic-plasmocytoid-dendritic-cell-neoplasm-bpdcn-clinical-features-and-histopathology-with-a-therapeutic-overview
#20
REVIEW
Gerardo Cazzato, Marialessandra Capuzzolo, Emilio Bellitti, Giovanni De Biasi, Anna Colagrande, Katia Mangialardi, Francesco Gaudio, Giuseppe Ingravallo
Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCNs) are a rare, highly aggressive hematological malignant neoplasm that primarily involve the skin, bone marrow, lymph nodes and even extra-nodal sites. The rarity and relative poor description of cases in the literature make it necessary to review and further studies that deeply investigate this entity not only in a histopathological but also molecular field. In August-September 2023, we searched MEDLINE, PubMed and Scopus for randomized controlled trials (RCTs), narrative and systematic reviews, meta-analyses, observational studies (either longitudinal or retrospective), and case series published in English in the last 25 years using the keywords BPDCN, PDCs, Blastic NK-cell lymphoma, agranular CD4+ NK leukemia/lymphoma, agranular CD4+ CD56+ hematodermic neoplasm/tumor...
December 8, 2023: Hematology Reports
journal
journal
43504
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.